← back to search

Volker Limmroth

St. Josef-Hospital · DE
Area of research
Pathology and Forensic Medicine · Psychiatry and Mental health
Research interest
Research interests include Multiple Sclerosis Research Studies, Migraine and Headache Studies, Trigeminal Neuralgia and Treatments, and Polyomavirus and related diseases.
h-index
56
citations
10,932
works
414
NIH funding
primary concept
email

Recent publications

Prehospital Levetiracetam Use in Adults With Status Epilepticus: Results of a Multicenter Registry.
2023cited by 2position: contributordoi
Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon β-1b: Observational Study.
2022cited by 4position: contributordoi
Correction: Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon β-1b: Observational Study (Preprint)
2022cited by 1position: contributordoi
Correction: Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon β-1b: Observational Study.
2022cited by 0position: contributordoi
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
Therapeutic Advances in Neurological Disorders 2021cited by 184position: middledoi
Thrombectomy in Extensive Stroke May Not Be Beneficial and Is Associated With Increased Risk for Hemorrhage
Stroke 2021cited by 62position: lastdoi
Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper)
Der Nervenarzt 2021cited by 24position: middledoi
Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions
Neurological Research and Practice 2021cited by 14position: middledoi
Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon β-1b: Observational Study (Preprint)
2021cited by 0position: contributordoi
Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity
Proceedings of the National Academy of Sciences 2020cited by 73position: middledoi
Assessment of Medication Adherence Using a Medical App Among Patients With Multiple Sclerosis Treated With Interferon Beta-1b: Pilot Digital Observational Study (PROmyBETAapp).
2019cited by 8position: contributordoi
Systematic evaluation of stroke thrombectomy in clinical practice: The German Stroke Registry Endovascular Treatment
International Journal of Stroke 2018cited by 109position: middledoi
Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation
Science Advances 2016cited by 182position: middledoi
Monitoring von Blutparametern unter verlaufsmodifizierender MS-Therapie
Der Nervenarzt 2016cited by 14position: middledoi
Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array
Genetic Epidemiology 2015cited by 16position: middledoi
Aktuelles zur Therapieumstellung bei Multipler Sklerose
Der Nervenarzt 2015cited by 5position: middledoi
Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab‐associated progressive multifocal leukoencephalopathy
Annals of Neurology 2014cited by 97position: middledoi
Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF
Multiple Sclerosis Journal 2014cited by 81position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 6 papers (2019–2023)Markus Schürks · 5 papers (2019–2022)Christian Mueller · Bayer AG5 papers (2019–2022)Kirsten Bayer-Gersmann · Institut Dr. Schauerte4 papers (2021–2022)Ralf Gold · Lead Discovery Center (Germany)3 papers (2014–2015)Martin Stangel · Novartis (Switzerland)3 papers (2014–2015)Tania Kümpfel · Imperial College London3 papers (2014–2015)Reinhard Hohlfeld · University of California, San Francisco3 papers (2014–2015) · 2 papers (2014–2014)Ortwin Adams · Medizinische Hochschule Hannover2 papers (2014–2014)Mike P. Wattjes · Humboldt-Universität zu Berlin2 papers (2014–2014) · 2 papers (2014–2014)Hans‐Peter Hartung · The University of Sydney2 papers (2014–2014)Clemens Warnke · Philipps University of Marburg2 papers (2014–2014)Mathias Mäurer · Johannes Gutenberg University Mainz2 papers (2014–2014)Bernd C. Kieseier · Novartis (Switzerland)2 papers (2014–2014)Christoph Kleinschnitz · Essen University Hospital2 papers (2014–2014)Tomas Olsson · Karolinska University Hospital2 papers (2014–2014) · 2 papers (2014–2014) · 2 papers (2014–2014)